GlassScriptPhysician profile
Richard Alan Snodgrass
NPI 1376535062
$1,225.35
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $861 · 2020: $349 · 2024: $16.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16.12.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $166.27 | 2019-2020 | |
| Pfizer INC. | $159.11 | 2019-2020 | |
| Lilly USA, LLC | $143.18 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $114.48 | 2019 | |
| Novo Nordisk INC | $109.84 | 2019 | |
| Eisai INC. | $76.57 | 2020 | |
| Merck Sharp & Dohme LLC | $55.14 | 2019-2020 | |
| Allergan, INC. | $52.92 | 2019-2020 | |
| Glaxosmithkline, LLC. | $44.14 | 2019 | |
| Mylan Specialty L.P. | $42.62 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $34.43 | 2019 | |
| Amgen INC. | $24.58 | 2019-2020 | |
| Abbvie INC. | $20.63 | 2019 | |
| Idorsia Pharmaceuticals US INC | $16.12 | 2024 | Quviviq |
| Supernus Pharmaceuticals, INC. | $12.75 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lupin INC. | $10.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Snodgrass listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.